X4 Pharmaceuticals, Inc. Common Stock
XFORStock
$3.83+165.31%52W
Market Cap$360.34M
P/E—
Div yield—
Beta0.37
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-11.96%
Price vs S&P 500 (4W)-4.06%
VGM Score48.59
Market Capitalization$360.34M
Earnings Surprise History
Q1 26-0.16est. -0.20
Analyst Recommendations
Mar 2026
Apr 2026
May 2026
Jun 2026
4.22
4.33
4.33
4.33
Industry Peers — Biological Products(180)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
XFORX4 Pharmaceuticals, Inc. Common Stock | C | D | B | $3.83 |
| AMGNAmgen Inc | C | C | C | $371.58 |
| GILDGilead Sciences Inc | C | B | C | $136.30 |
| ARGXargenx SE American Depositary Shares | D | A | B | $857.97 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $179.18 |
| BIIBBiogen Inc. Common Stock | B | D | B | $208.92 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.56 |
| MRNAModerna, Inc. Common Stock | D | B | B | $63.15 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $171.55 |
| EXELExelixis Inc | C | B | B | $55.68 |
| TECHBio-Techne Corp. | D | C | B | $71.77 |
About
X4 Pharmaceuticals develops therapies for rare immune system disorders. Its lead candidate mavorixafor is an oral, once-daily CXCR4 antagonist designed to increase white blood cell mobilization from the bone marrow. The company has two additional CXCR4-based candidates in preclinical development.